Vanguard Value ETF (the Fund) is an exchange-traded share class of Vanguard Value Index Fund, which employs a passive management or indexing investment approach designed to track the performance of the MSCI US Prime Market Value Index (the Index). The Index is a diversified index of value stocks of predominantly large United States companies. The Index represents the value companies of the MSCI US Prime Market 750 Index. The MSCI US Prime Market 750 Index represents the universe of predominantly large-capitalization companies in the United States equity market. The Fund attempts to replicate the target Index by investing all, or substantially all, of its assets in the stocks that make up the Index, holding each stock in approximately the same proportion as its weighting in the Index. The Fund may invest, to a limited extent, in stock futures and options contracts, warrants, convertible securities and swap agreements. The Fund's investment advisor is Vanguard Quantitative Equity Group.
Basic Details
Issuer Vanguard
Fund NameVanguard Value ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:VTV
Inception Date1/26/2004
Fund ManagerWalter Nejman, Gerard C. O'Reilly
Phone+1-800-5231036
Fund Focus
Asset ClassEquity
BenchmarkCRSP U.S. Large Cap Value Index
CategorySize and Style
FocusLarge Cap
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$56.37 billion
Average Daily Volume$1.42 million
Discount/Premium-0.06%
ETF Expenses
Management Fee0.03%
Other Expenses0.01%
Total Expenses0.04%
Fee Waiver0.00%
Net Expenses0.04%
Administrator, Advisor and Custodian
AdministratorThe Vanguard Group, Inc.
AdvisorThe Vanguard Group, Inc.
CustodianJPMorgan Chase Bank, N.A.
DistributorVanguard Marketing Corporation
Transfer AgentThe Vanguard Group, Inc.
Trustee
Lead Market Maker
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.
